| Literature DB >> 26556188 |
Harkiran Kaur1, Gurpreet Kaur1.
Abstract
Polyphenols constitute a family of natural substances distributed widely in plant kingdom. These are produced as secondary metabolites by plants and so far 8000 representatives of this family have been identified. Recently, there is an increased interest in the polyphenols because of the evidence of their role in prevention of degenerative diseases such as neurodegenerative diseases, cancer, and cardiovascular diseases. Although a large number of drugs are available in the market for treatment of these diseases, however, the emphasis these days is on the exploitation of natural principles derived from plants. Most polyphenols show low in vivo bioavailability thus limiting their application for oral drug delivery. This low bioavailability could be associated with low aqueous solubility, first pass effect, metabolism in GIT, or irreversible binding to cellular DNA and proteins. Therefore, there is a need to devise strategies to improve oral bioavailability of polyphenols. Various approaches like nanosizing, self-microemulsifying drug delivery systems (SMEDDS), microencapsulation, complexation, and solid dispersion can be used to increase the bioavailability. This paper will highlight the various methods that have been employed till date for the solubility enhancement of various polyphenols so that a suitable drug delivery system can be formulated.Entities:
Year: 2014 PMID: 26556188 PMCID: PMC4590825 DOI: 10.1155/2014/180845
Source DB: PubMed Journal: J Pharm (Cairo) ISSN: 2090-9918
Pharmacokinetic properties of polyphenols.
| Polyphenol | Solubility ( | Dose ( |
|
| References |
|---|---|---|---|---|---|
| Phenolic acid | |||||
| Ellagic acid | 9.3 | 44.67 | 0.036 | 1.98 | [ |
| Stilbenes | |||||
| Resveratrol | 30 | 109.5 | 0.031 | 0.5 | [ |
| Flavonols | |||||
| Quercetin | 0.3 | 255 | 0.74 | 0.7 | [ |
| Flavones | |||||
| Apigenin | 2.16 | 65.8 | 0.12 | 7.2 | [ |
| Flavanones | |||||
| Hesperetin | 1.4 | 727 | 1.3 | 5.8 | [ |
| Naringenin | 45 | 166 | 0.2 | 5.0 | [ |
| Anthocyanins | |||||
| Cyanidin-3-rutinoside | — | 137 | 0.05 | 1.5 | [ |
| Delphinidin-3-rutinoside | — | 182 | 0.07 | 1.8 | [ |
| Isoflavones | |||||
| Genistein | 0.81 | 70 | 0.75 | 6.5 | [ |
| Daidzein | 8.215 | 98 | 0.79 | 6.5 | [ |
Strategies to improve solubility of polyphenols.
| Method | Procedure | Advantages | Disadvantages | Example | Reference |
|---|---|---|---|---|---|
| Nanoparticles | [ | ||||
|
| |||||
| Evaporative precipitation into aqueous solution | Spraying of drug solution through an atomizer into an aqueous solution containing stabilizer at high temperature. | High dissolution rate, high surface area, enhanced wettability. | Require stabilizers, lack of controlled release, not suitable for thermolabile drugs | Nanosuspension of quercetin | [ |
|
| |||||
| High pressure homogenization | Precipitation of drug by addition of antisolvent in the drug solution leading to formation of unstable form of drug which is stabilized by means of single/repeated application of high energy followed by thermal relaxation (annealing). | Reduced particle size, enhanced dissolution, no crystal growth | Long processing time, introduction of impurities, high energy requirements, chemical degradation | Nanosuspension of quercetin | [ |
|
| |||||
| Antisolvent method | |||||
| Antisolvent | Addition of antisolvent to a solution of drug and solvent at a particular flow rate under constant stirring leading to precipitation of drug which is then filtered to collect nanoparticles. | Reduced particle size, high dissolution rate, high surface area, reduced crystallinity, faster onset of action | Contamination due to filtration | Nanoparticles of hesperetin | [ |
| Evaporative | Mixing of a water miscible solvent containing drug with an antisolvent followed by evaporation of solvents. | Decreased particle size, enhanced surface area, improved dissolution | Particle growth due to remaining organic solvent in suspension | Curcumin nanoparticles | [ |
| Supercritical | Precipitation of drug from drug solution by mixing it with a compressed fluid at its supercritical conditions. Diffusion of solvent into antisolvent phase leads to drug precipitation due to low solubility of drug in antisolvent. | High product purity, controlled crystal polymorphism, possible processing of thermolabile molecules, single step process | Toxicity and flammability of solvents, poor control of particle morphology, incomplete removal of residual solvent | Apigenin nanocrystals | [ |
|
| |||||
| Solid dispersion | Formation of eutectic mixtures of drugs with hydrophilic carriers by melting their physical mixtures | Particle size reduction, improved wettability, enhanced dissolution, higher porosity | Decrease in dissolution on aging, crystal growth upon moisture absorption, demixing, phase separation | Solid dispersion of ellagic acid | [ |
|
| |||||
| Self-microemulsifying drug delivery systems | Gentle mixing of drug, oil, surfactant, and cosurfactant in aqueous media leading to formation of o/w microemulsion of drug droplets with mean droplet size <100 nm. | Higher bioavailability, improved absorption, oral administration using gelatin capsules | Surfactant toxicity, tedious manufacturing method, interaction with capsule shell | Curcumin | [ |
Figure 1Chemical structure of polyphenols.
Different methods for solid dispersions of ellagic acid [37].
| Method | Composition | Procedure |
|---|---|---|
| Spray-dried solid dispersion | Acetone : ethanol (1 : 4 v/v) solution, ellagic acid, polyvinylpyrrolidone (PVP), carboxymethyl cellulose acetate butyrate (CMCAB), hydroxypropyl methyl cellulose acetate succinate (HPMCAS) | Acetone : ethanol solution was used to dissolve mixtures of EA/polymer followed by spray drying of the resultant dispersion under operating conditions of 90°C inlet temperature, 57–60°C outlet temperature, 9 mL/min feed rate, and 350 L/h nitrogen flow. |
|
| ||
| Coprecipitated solid dispersion | Ellagic acid, tetrahydrofuran (THF), cellulose acetate adipate propionate (CAAdP) | A mixture of EA/CAAdP was dissolved in THF followed by dropwise addition of the solution in deionized water with stirring. |
|
| ||
| Solid dispersion by rotary evaporation | Ellagic acid (20 mg), PVP (90 mg), CAAdP (90 mg), acetonitrile : ethanol (1 : 1 v/v) solution (40 mL) | EA, PVP, and CAAdP were dissolved in acetonitrile : ethanol solution followed by concentrating the solution with rotary evaporation |
Figure 2Classification and chemical structure of flavonoids.
Figure 3Steps involved in SAS method for preparation of nanoparticles [55].
Figure 4(a) Depicting the effect of various parameters on particle size and solubility of hesperetin by APSP method [65]. (b) Depicting the effect of various parameters on particle size and solubility of hesperetin by EPN method [65].
Figure 5APSP and EPN techniques for nanoparticle formulation of curcumin [92].
Figure 6Formulation of curcumin solid dispersions [94].